Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Gossamer Bio (4GB0) Stock Price & Analysis

10 Followers

4GB0 Stock Chart & Stats

€8.84€0.00(0.00%)
At close: 5:30 PM GMT+1
€7.5€10€12.5€15Jul 21Jul 30Aug 17Sep 2Sep 8Sep 23Oct 12
Day’s Range
EUR 8.84 - EUR 10.39
52-Week Range
EUR 6.77 - EUR 253.92
Previous Close
EUR 8.84
Volume
N/A
Average Volume (3M)
8
Market Cap
EUR 62.12M
Enterprise Value
EUR 67.04M
Total Cash (Recent Filing)
EUR 51.19M
Total Debt (Recent Filing)
EUR 40.85M
Price to Earnings (P/E)
―
Beta
0.09
Next Earnings
Mar 12, 2027 (Est.)
EPS Estimate
-2.26
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress

Submitting the first NDA moves seralutinib from late-stage development into formal FDA review, creating a defined regulatory pathway for the lead asset. If the application is accepted and approved, Gossamer could transition toward commercialization in PAH and establish a larger strategic base.

Financing Runway

The structured financing provides committed and milestone-linked capital for regulatory work, late-stage development, and potential commercialization. Extending expected funding into 2028 gives management more time to execute on seralutinib without relying solely on immediate additional fundraising.

Improved Revenue

The sharp TTM revenue improvement indicates better commercial traction than in prior periods and provides evidence that the business has generated meaningful operating revenue. Continued growth would strengthen the platform’s ability to support development investment, although the historical revenue path remains uneven.

Bears Say

Persistent Cash Burn

Heavy operating and free cash flow losses show that the company is not yet self-funding its activities and remains dependent on external capital. Persistent burn can reduce financial flexibility, increase financing needs, and make execution more sensitive to regulatory or development delays.

Severely Stressed Balance Sheet

The deterioration from positive equity to a negative or zero reported position signals limited balance-sheet flexibility and a weakened capital structure. Although TTM debt declined, the sharp reduction in total assets means the company has less financial cushion to absorb setbacks or fund operations internally.

Shareholder Dilution

The approved financing structure can materially expand the share count through pre-funded warrants, FDA approval warrants, and preferred-stock conversions. While this supports liquidity and development, it can reduce existing holders’ ownership and constrain per-share participation in future value creation.

Gossamer Bio News

4GB0 FAQ

What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was €6.77 and its highest was €253.92 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is €62.12M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s next earnings report is estimated for Mar 12, 2027 (not yet confirmed), which is in 120 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on Nov 10, 2026. The company reported -€6.633 earnings per share for the quarter, missing the consensus estimate of -€3.416 by -€3.216.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -2.26.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 6,110,584 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -€6.633 in its last earnings report, missing expectations of -€3.416. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gossamer Bio?
Hedge funds hold Gossamer Bio shares: the largest hedge-fund position in Gossamer Bio is 950,256,772 shares, and hedge funds decreased their holdings by 3.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology